China Drug Infusion System Market Summary

As per Market Research Future analysis, the China drug infusion-system market size was estimated at 740.25 USD Million in 2024. The China drug infusion-system market is projected to grow from 779.78 USD Million in 2025 to 1312.0 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 5.3% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The China The drug infusion-system market is poised for growth. This growth is driven by technological advancements and increasing demand for home healthcare solutions.

Technological advancements are enhancing the efficiency and safety of drug infusion systems.
The largest segment in the market is the hospital-based infusion systems, while home healthcare solutions are the fastest-growing segment.
Regulatory support is fostering innovation and ensuring patient safety in drug delivery systems.
Rising demand for home healthcare solutions and the integration of smart technologies are key drivers of market growth.

Market Size & Forecast

2024 Market Size	740.25 (USD Million)
2035 Market Size	1312.0 (USD Million)
CAGR (2025 - 2035)	5.34%

Major Players

Baxter International (US), B. Braun Melsungen AG (DE), Medtronic (US), Smiths Medical (US), Fresenius Kabi (DE), Terumo Corporation (JP), ICU Medical (US), Halyard Health (US), Zyno Medical (US)

Our Impact

Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals

Partnering with 2000+ Global Organizations Each Year

30K+ Citations by Top-Tier Firms in the Industry

China Drug Infusion System Market Trends

The drug infusion-system market is experiencing notable growth. In recent years, there has been a marked shift towards automated and smart infusion systems, which enhance precision in medication delivery. This trend is largely influenced by the rising prevalence of chronic diseases, necessitating more effective treatment options. Furthermore, the integration of digital health technologies into infusion systems appears to be transforming patient management, allowing for real-time monitoring and data collection. As healthcare providers seek to improve patient outcomes, the adoption of these innovative systems is likely to accelerate. Moreover, regulatory support from government bodies is fostering a conducive environment for the development and deployment of advanced infusion technologies. Initiatives aimed at enhancing healthcare infrastructure and promoting research and development are expected to bolster the drug infusion-system market. The focus on patient safety is driving the demand for sophisticated infusion devices. Additionally, the reduction of medication errors is also a key factor. As the market evolves, stakeholders must remain vigilant to emerging trends and adapt their strategies accordingly to capitalize on the opportunities presented by this dynamic landscape.

Technological Advancements

The drug infusion-system market is witnessing rapid technological advancements, particularly in the realm of smart infusion devices. These systems are designed to enhance accuracy and reduce the risk of medication errors, which is crucial in clinical settings. The integration of features such as dose error reduction systems and wireless connectivity is becoming increasingly common, allowing for better patient monitoring and data management.

Regulatory Support

Regulatory bodies are playing a pivotal role in shaping the drug infusion-system market. Supportive policies and guidelines are being established to ensure the safety and efficacy of infusion devices. This regulatory framework not only encourages innovation but also instills confidence among healthcare providers and patients, thereby driving market growth.

Focus on Patient Safety

There is a growing emphasis on patient safety within the drug infusion-system market. Healthcare providers are increasingly prioritizing systems that minimize the risk of adverse events associated with medication administration. This focus is leading to the development of more sophisticated infusion technologies that enhance monitoring capabilities and improve overall treatment outcomes.

China Drug Infusion System Market Drivers

Integration of Smart Technologies

The integration of smart technologies into drug infusion systems is transforming the landscape of the market in China. Advanced features such as real-time monitoring, automated dosage adjustments, and connectivity with mobile applications are becoming increasingly prevalent. These innovations enhance the efficiency and accuracy of drug delivery, thereby improving patient outcomes. The market is projected to grow as healthcare facilities adopt these smart systems to streamline operations and reduce medication errors. It is estimated that the adoption of smart infusion systems could lead to a reduction in adverse drug events by up to 30%. This technological evolution is likely to drive the drug infusion-system market forward, as healthcare providers seek to leverage technology for better patient care.

Government Initiatives and Funding

Government initiatives and funding play a crucial role in shaping the drug infusion-system market in China. The government has been actively promoting healthcare reforms aimed at improving access to advanced medical technologies. Increased funding for healthcare infrastructure and innovation is likely to enhance the availability of drug infusion systems across various healthcare settings. Additionally, public health campaigns aimed at raising awareness about the benefits of infusion therapy are expected to further stimulate market growth. With the government's commitment to enhancing healthcare delivery, the drug infusion-system market is poised for expansion, potentially reaching a valuation of $2 billion by 2027.

Growing Focus on Personalized Medicine

The drug infusion-system market in China is witnessing a growing focus on personalized medicine, which tailors treatment to individual patient needs. This approach is becoming increasingly relevant as healthcare providers recognize the importance of customized therapies in improving patient outcomes. Infusion systems that can accommodate personalized drug regimens are in high demand, as they allow for precise dosing and monitoring. The trend towards personalized medicine is likely to drive innovation within the drug infusion-system market, as manufacturers develop systems that can adapt to varying patient requirements. This shift is expected to contribute to a market growth rate of approximately 9% over the next five years, reflecting the increasing emphasis on individualized treatment strategies.

Increasing Prevalence of Chronic Diseases

The drug infusion-system market in China is significantly influenced by the rising prevalence of chronic diseases such as diabetes, cancer, and cardiovascular disorders. According to recent statistics, chronic diseases account for approximately 80% of all healthcare expenditures in the country. This alarming trend necessitates effective management strategies, including the use of drug infusion systems for continuous medication delivery. As the population ages and lifestyle-related health issues become more common, the demand for reliable infusion systems is expected to escalate. The market is anticipated to grow at a CAGR of around 8% over the next few years, driven by the urgent need for effective treatment options for chronic conditions.

Rising Demand for Home Healthcare Solutions

The drug infusion-system market in China is experiencing a notable surge in demand for home healthcare solutions. This trend is driven by an increasing aging population, which is projected to reach 400 million by 2040. As more patients prefer receiving treatment at home, the market for drug infusion systems is likely to expand significantly. Home healthcare not only reduces hospital visits but also enhances patient comfort and satisfaction. The convenience of administering medications at home is appealing to both patients and healthcare providers. Consequently, the drug infusion-system market is expected to witness a compound annual growth rate (CAGR) of approximately 10% over the next five years, reflecting the growing preference for home-based care solutions.

Market Segment Insights

By Product Type: Syringe infusion system (Largest) vs. Elastomeric infusion system (Fastest-Growing)

In the China drug infusion-system market, the distribution of market share among product types showcases the syringe infusion system as the largest segment, attributed to its widespread utilization in healthcare facilities. Following closely is the disposable infusion system, alongside the emerging elastomeric infusion system, which has gained traction due to its user-friendly features and efficiency in drug delivery. Other notable segments include peristaltic and multi-channel pumps, both contributing to a diverse market landscape. The growth trends in this segment are driven by advancements in technology and an increase in chronic diseases requiring continuous drug administration. The rising preference for home care settings has also propelled demand for portable and user-centric infusion systems, with elastomeric infusion systems leading the charge as the fastest-growing category in the market, indicating a shift towards more flexible treatment options.

Syringe infusion system (Dominant) vs. Elastomeric infusion system (Emerging)

The syringe infusion system is a dominant player in the China drug infusion-system market, favored for its reliability and accuracy in medication delivery. This system is commonly used in hospitals and outpatient settings, offering a straightforward solution for healthcare providers. In contrast, the elastomeric infusion system is an emerging segment, characterized by its autonomy and ease of use. These systems, which utilize a balloon-like device to deliver medication, are increasingly recognized for their benefits in patient-controlled administration and convenience. The growth of the elastomeric infusion system is indicative of a shift towards more innovative, patient-friendly solutions that enhance treatment efficacy and compliance.

By Application: Oncology/Chemotherapy (Largest) vs. Diabetes (Fastest-Growing)

In the China drug infusion-system market, the Oncology/Chemotherapy segment holds the largest market share, driven by the rising incidence of cancer cases and the increasing adoption of advanced treatment protocols. Following closely is the Diabetes segment, which is experiencing robust growth due to the alarming rise in diabetes prevalence and the demand for effective management solutions. This competitive landscape highlights the importance of innovation in drug delivery systems for chronic conditions. Growth trends indicate that while Oncology/Chemotherapy remains dominant, the Diabetes sector is set to outpace traditional segments significantly. Factors such as increased healthcare expenditure, technological advancements in drug delivery, and expanding patient awareness contribute to the rapid growth of the diabetes infusion systems. Furthermore, emerging trends in personalized medicine and continuous monitoring are expected to propel the market forward, particularly for the Diabetes segment.

Oncology/Chemotherapy (Dominant) vs. Diabetes (Emerging)

The Oncology/Chemotherapy segment is characterized by a diverse range of infusion systems designed for administering chemotherapeutic agents. Its dominance stems from extensive research and development investments, driving innovation in drug delivery techniques that enhance efficacy and patient comfort. Conversely, the Diabetes segment is emerging rapidly, primarily due to the increasing prevalence of diabetes among the population. The infusion systems in this category are crucial for providing consistent insulin delivery to manage blood sugar levels effectively. The growing trend towards home care and the development of user-friendly, advanced delivery systems are key drivers that support the rising popularity of diabetes products, positioning them favorably for future growth.

By Mode of administration: Intravenous (Largest) vs. Subcutaneous (Fastest-Growing)

The China drug infusion-system market demonstrates a diverse distribution of market share among its mode of administration segments. Intravenous administration commands the largest share, as it is the most commonly used method for delivering medications directly into the bloodstream. Subcutaneous administration is witnessing notable growth, appealing to patient convenience and the rise in home care and self-administration practices. Arterial, epidural, and other methods contribute to the market but remain comparatively smaller in share. Growth trends in the mode of administration segment are driven by factors such as an increased demand for active and chronic disease management, advancements in infusion technology, and an emphasis on non-invasive treatment methods. Intravenous delivery maintains its prominence due to its efficiency in drug administration. In contrast, the subcutaneous route is emerging rapidly, supported by innovations that enhance patient experience and facilitate outpatient care, making it a preferred option for many healthcare providers.

Intravenous (Dominant) vs. Subcutaneous (Emerging)

Intravenous administration is recognized as the dominant method in the China drug infusion-system market, primarily due to its wide acceptance in acute care settings and the efficiency it offers in drug delivery. This method allows for rapid onset of action, making it crucial for critically ill patients requiring immediate treatment. Conversely, the subcutaneous method is emerging as a viable alternative, particularly appealing for long-term treatments and patient self-management. Its growth is fueled by technological advancements that make devices easier to use and more comfortable for patients. Both methods highlight significant trends in patient-centered care, with intravenous methods standing out for acute interventions, while subcutaneous administration is gaining traction in managing chronic conditions outside of clinical settings.

By End-user: Hospitals (Largest) vs. Ambulatory Surgical Centers (Fastest-Growing)

In the China drug infusion-system market, hospitals hold the largest share, dominating the overall distribution of end-user segments. This is largely attributed to their extensive infrastructure and high volume of inpatient procedures requiring drug infusion systems. Ambulatory surgical centers, while smaller in market share, are rapidly gaining ground, driven by the increasing preference for outpatient services that promise lower costs and shorter recovery times. Growth trends indicate a robust expansion in both hospitals and ambulatory surgical centers. The shift towards minimally invasive surgeries and outpatient care is propelling the demand for advanced drug infusion systems. Hospitals are adapting to technological advancements, while ambulatory surgical centers benefit from the rising patient preference for convenience and efficiency in healthcare delivery, marking them as a significant player in the market's future.

Hospitals (Dominant) vs. Ambulatory Surgical Centers (Emerging)

Hospitals, as the dominant segment in the China drug infusion-system market, showcase a comprehensive integration of advanced medical technology that caters to diverse inpatient needs. They typically facilitate a wide range of drug infusion therapies, supported by specialized staff and vast resources. In contrast, ambulatory surgical centers are emerging as pivotal players, focusing on cost-effective and efficient treatment for outpatient procedures. These centers are characterized by their streamlined operations and patient-centric services, offering a more accessible alternative to traditional hospital settings. The growing trend among patients to seek quicker recovery options and reduced hospital stays is likely to bolster the market position of ambulatory surgical centers significantly in the coming years.

Get more detailed insights about China Drug Infusion System Market

Request Free Sample

Key Players and Competitive Insights

The drug infusion-system market in China is characterized by a dynamic competitive landscape, driven by technological advancements and increasing healthcare demands. Major players such as Baxter International (US), B. Braun Melsungen AG (DE), and Medtronic (US) are strategically positioned to leverage innovation and regional expansion. Baxter International (US) focuses on enhancing its product portfolio through continuous innovation, while B. Braun Melsungen AG (DE) emphasizes partnerships to strengthen its market presence. Medtronic (US) is actively pursuing digital transformation initiatives, which collectively shape a competitive environment that prioritizes advanced solutions and customer-centric approaches.Key business tactics within this market include localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The competitive structure appears moderately fragmented, with several key players exerting influence over market dynamics. This fragmentation allows for a diverse range of products and services, catering to varying customer needs while fostering healthy competition among established and emerging companies.

In September Baxter International (US) announced the launch of a new infusion pump designed to improve patient safety and streamline workflows in clinical settings. This strategic move underscores Baxter's commitment to innovation and positions the company to capture a larger market share by addressing critical healthcare challenges. The introduction of this advanced technology is likely to enhance Baxter's competitive edge in a rapidly evolving market.

In October B. Braun Melsungen AG (DE) expanded its manufacturing capabilities in China by investing €50 million in a new facility. This investment not only signifies B. Braun's dedication to local production but also aims to meet the growing demand for infusion systems in the region. By localizing its operations, B. Braun is expected to improve supply chain efficiency and reduce lead times, thereby enhancing its competitive positioning.

In August Medtronic (US) entered into a strategic partnership with a leading Chinese healthcare provider to integrate AI-driven analytics into its infusion systems. This collaboration is anticipated to enhance patient monitoring and optimize treatment protocols, reflecting Medtronic's focus on digital health solutions. The integration of AI technology is likely to set a new standard in the market, further differentiating Medtronic from its competitors.

As of November current trends in the drug infusion-system market include a strong emphasis on digitalization, sustainability, and AI integration. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition to a focus on innovation, technology, and supply chain reliability. This transition may redefine market dynamics, compelling companies to invest in advanced solutions that enhance patient outcomes and operational efficiency.

Key Companies in the China Drug Infusion System Market include

Industry Developments

Recent developments in the China Drug Infusion System Market reflect a dynamic landscape marked by increasing technological advancements and regulatory changes. Companies like Becton Dickinson, Medtronic, and Fresenius Kabi are ramping up their product offerings to meet the growing demand for innovative drug delivery systems driven by an expanding healthcare infrastructure. According to government sources, the Chinese government continues to enhance its healthcare policies, which is positively impacting the market growth.

In terms of mergers and acquisitions, there have been notable activities, such as Zhejiang Shunfeng's acquisition of Hunan Jisheng Medical in September 2023, further consolidating its market position. Additionally, B. Braun has expanded its operations in China by establishing new production facilities to increase local manufacturing capabilities, enhancing supply chain efficiency. The Chinese Drug Infusion System Market is projected to witness significant growth due to rising chronic disease prevalence and increasing healthcare expenditures, with companies like Johnson and Johnson and Terumo actively participating in this growth trajectory.

Over the past few years, investments in Research and Development have surged, indicating a robust focus on innovative solutions to improve patient outcomes.

Future Outlook

China Drug Infusion System Market Future Outlook

The Drug Infusion System Market in China is projected to grow at a 5.34% CAGR from 2025 to 2035, driven by technological advancements and increasing healthcare demands.

New opportunities lie in:

Development of smart infusion pumps with IoT connectivity
Expansion of home healthcare infusion services
Integration of AI for personalized medication delivery

By 2035, the market is expected to achieve substantial growth and innovation.

Market Segmentation

China Drug Infusion System Market End-user Outlook

Hospitals
Ambulatory Surgical Centers
Diagnostic centers
Others

China Drug Infusion System Market Application Outlook

Oncology/Chemotherapy
Diabetes
Analgesia
Nutrition
Hematology
Pediatrics
Others

China Drug Infusion System Market Product Type Outlook

Elastomeric infusion system
Disposable infusion system
Syringe infusion system
Peristaltic pump
Multi-channel pump
Patient-Controlled Analgesia (PCA) pump
Insulin pump
Implantable infusion system

China Drug Infusion System Market Mode of administration Outlook

Intravenous
Subcutaneous
Arterial
Epidural
Others

Report Scope

MARKET SIZE 2024	740.25(USD Million)
MARKET SIZE 2025	779.78(USD Million)
MARKET SIZE 2035	1312.0(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)	5.34% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Million
Key Companies Profiled	Baxter International (US), B. Braun Melsungen AG (DE), Medtronic (US), Smiths Medical (US), Fresenius Kabi (DE), Terumo Corporation (JP), ICU Medical (US), Halyard Health (US), Zyno Medical (US)
Segments Covered	Product Type, Application, Mode of administration, End-user
Key Market Opportunities	Integration of smart technology in drug infusion systems enhances patient safety and operational efficiency.
Key Market Dynamics	Rising demand for advanced drug infusion systems driven by regulatory changes and technological innovations in healthcare.
Countries Covered	China

FAQs

What is the projected market valuation for the China drug infusion-system market in 2035?

The projected market valuation for the China drug infusion-system market in 2035 is $1312.0 Million.

What was the overall market valuation in 2024?

The overall market valuation in 2024 was $740.25 Million.

What is the expected CAGR for the China drug infusion-system market during the forecast period 2025 - 2035?

The expected CAGR for the China drug infusion-system market during the forecast period 2025 - 2035 is 5.34%.

Which product type had the highest valuation in 2024?

In 2024, the disposable infusion system had the highest valuation at $148.06 Million.

What is the projected valuation for the oncology/chemotherapy application by 2035?

The projected valuation for the oncology/chemotherapy application by 2035 is $263.0 Million.

Which end-user segment is expected to dominate the market in 2035?

The hospitals segment is expected to dominate the market in 2035 with a projected valuation of $683.4 Million.

What was the valuation of the insulin pump segment in 2024?

The valuation of the insulin pump segment in 2024 was $37.01 Million.

Which key player is known for its leadership in the drug infusion-system market?

Baxter International is recognized for its leadership in the drug infusion-system market.

What is the projected valuation for the multi-channel pump segment by 2035?

The projected valuation for the multi-channel pump segment by 2035 is $130.0 Million.

How does the valuation of the subcutaneous mode of administration compare in 2024 and 2035?

The valuation of the subcutaneous mode of administration is expected to increase from $148.05 Million in 2024 to $250.0 Million in 2035.

Author

Author

Satyendra Maurya

Research Analyst

An accomplished research analyst with high proficiency in market forecasting, data visualization, competitive benchmarking, and others. He holds a pronounced track record in research and consulting projects for sectors such as life sciences, medical devices, and healthcare IT. His capabilities in qualitative and quantitative analysis have resulted in positive client outcomes. Working on niche market trends, opportunities, sales, and forecasted value is part of his skill set.

Co-Author

Garvit Vyas

Vice President - Operations

Garvit Vyas is a Research Analyst with experience in working across multiple industry domains in the market research sector. Over the past four years, he has been actively involved in analyzing diverse markets, gathering industry insights, and contributing to the development of comprehensive research reports. His work includes studying market trends, evaluating competitive landscapes, and supporting data-driven business insights. In the early phase of his career, Garvit worked on cross-domain research projects, which helped him build a strong foundation in market analysis, data interpretation, and industry intelligence across various sectors. Later, he transitioned into the Quality Control (QC) function, where he focuses on reviewing and refining research reports and marketing collaterals to ensure accuracy, consistency, and high editorial standards. His responsibilities include validating research data, improving report structure, and maintaining the overall quality of published content. Garvit is committed to maintaining strong research integrity and delivering reliable insights that support informed business decision-making.

Get In Touch

Leave a Comment